selected scholarly activity
-
chapters
- Mantle Cell Lymphoma. 347-351. 2008
-
conferences
- Fitness Assessment of Elderly Patients with AML and Outcomes. Blood. 3379-3379. 2021
- Guiding the Standardization in Acute Leukemia Service Delivery through the Development of Organizational Requirements. Blood. 3013-3013. 2021
- AML-303: Systematic Review of Frailty Assessment Tools for Elderly Patients with Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia. S200-S200. 2020
- Systematic Review of Frailty Assessment Tools for Elderly Patients with Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia. S200-S200. 2020
- A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma. Blood. 3121-3121. 2019
- Undertreatment of Older Patients with Newly-Diagnosed Multiple Myeloma: Real World Evidence from a Canadian Registry Cohort. Blood. 268-268. 2019
- Developing and evaluating new models of care in hematology.. Journal of Clinical Oncology. 53-53. 2017
- Funding model for stem cell transplant.. Journal of Clinical Oncology. 22-22. 2017
- Granulocyte Colony-Stimulating Factor (GCSF) Use with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone +/- Rituximab (CHOP±R) Treatment for Aggressive Non-Hodgkin's Lymphoma (aNHL). Blood. 3038-3038. 2016
- Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial. Blood. 690-690. 2016
- Selinexor Shows Synergy in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma. Blood. 3330-3330. 2016
- Selinexor in Combination with Bortezomib and Dexamethasone (SdB) Demonstrates Significant Activity in Patients with Refractory Multiple Myeloma (MM) Including Proteasome-Inhibitor Refractory Patients: Results of the Phase I Stomp Trial. Blood. 977-977. 2016
- A PHASE 1B/2 STUDY OF SELINEXOR IN COMBINATION WITH BACKCONE THERAPIES FOR TREATMENT OF RELAPSED/REFACTORY MULTIPLE MYELOMA. Haematologica. 84-84. 2016
- Developing and evaluating new models of care in hematology.. Journal of Clinical Oncology. e21557-e21557. 2016
- A Phase II Study of AT9283, an Aurora Kinase Inhibitor, in Patients with Relapased or Refractory Multiple Myloma; NCIC Clinical Trials Group IND.191. Blood. 5734-5734. 2014
- A Randomized Trial Of Rituximab Vs Observation Following Autologous Stem Cell Transplantation (ASCT) For Relapsed Or Refractory CD20-Positive B Cell Lymphoma: Final Results Of NCIC CTG LY.12. Blood. 155-155. 2013
- Cost-Utility Of Bortezomib In Induction Treatment Prior To Autologous Stem-Cell Transplantation (ASCT) In Previously Untreated Multiple Myeloma Patients In Canada. Blood. 1735-1735. 2013
- The use of preoperative erythropoiesis-stimulating agents (ESAs) in patients who underwent knee or hip arthroplasty a meta-analysis of randomized clinical trials. Journal of Thrombosis and Haemostasis. 807-807. 2013
- THE USE OF PREOPERATIVE ERYTHROPOIESIS-STIMULATING AGENTS ( ESAS) IN PATIENTS WHO UNDERWENT KNEE OR HIP ARTHROPLASTY. Haematologica. 191-191. 2013
- Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: Final Results of the Randomized Phase III NCIC CTG Study LY12. Blood. 745-745. 2012
- Comparison of Comorbidity Scores and the Impact of Comorbidities on Length of Stay and Survival in Patients with Non-Hodgkin's Lymphoma Treated with Autologous Stem Cell Transplant. Blood. 917-917. 2011
- Empiric Antifungal Therapy with Amphotericin B in the Era of Fluconazole Prophylaxis: a Cohort Study in Adults with Acute Myeloid Leukemia Treated within An Institutional Antifungal Policy. Blood. 566-566. 2009
- Determining Patterns of Therapy Choice in Patients Treated for Early Stage, Aggressive Histology Non-Hodgkin's Lymphoma. International Journal of Radiation Oncology Biology Physics. S484-S485. 2009
- 17 DETERMINING PATTERNS OF THERAPY CHOICE IN PATIENTS TREATED FOR EARLY STAGE, AGGRESSIVE HISTOLOGY NONHODGKIN'S LYMPHOMA. Radiotherapy and Oncology. S6-S6. 2009
- Bortezomib is active in Waldenstrom's Macroglobulinemia (WM) - Results of a National Cancer Institute of Canada (NCIC) phase II study in previously untreated or treated WM.. Journal of Clinical Oncology. 432S-432S. 2006
- Antitumor activity of bortezomib (PS-341; Velcade) in a phase II study of patients with previously untreated or treated Waldenstrom's macroglobulinemia (WM). Blood. 896A-896A. 2004
- Phase II Trial of Bortezomib in Mantle Cell Lymphoma.. Blood. 608-608. 2004
- The Effect of Prophylactic Administration of Myeloid Growth Factors Following Autologous Stem Cell Transplantation for Patients with Hematological Malignancies: A Systematic Review.. Blood. 2192-2192. 2004
- Treatment of the Chronic Phase of Chronic Myeloid Leukemia with an Intermittent Schedule of Recombinant Interferon Alfa-2b and Cytarabine: Results from CALGB Study 9013. Leukemia and Lymphoma. 39-48. 2003
- A strategy of peripheral blood stem cell transplantation is cost-effective compared to melphalan and prednisone in younger patients with multiple myeloma.. Blood. 846A-846A. 2000
- Assessment of clinical trial inclusion criteria to a cohort of lymphoma patients undergoing autologous transplantation: Are trial results generalized to other patient populations?. Blood. 132A-132A. 2000
- Patients with multiple myeloma transplanted with increased numbers of PBPC demonstrate early recovery of total lymphocytes.. Blood. 335B-335B. 2000
- Seropositive symmetrical inflammatory polyarthritis appearing after treatment with fludarabine in a patient with non-Hodgkin's lymphoma.. Blood. 241B-241B. 2000
- Loss of CD34(+)/CD38(-) cells during ex vivo expansion of purified CD34(+) stem cells using adenoviral-based gene transfer of stem cell factor to bone marrow stromal cells.. Blood. 151A-151A. 1998
-
journal articles
- Comparing the clinical trial efficacy versus real-world effectiveness of treatments for multiple myeloma: a population-based study.. Haematologica. 2024
- Developing Organizational Requirements to Standardize Delivery and Improve Quality of Acute Leukemia Care in Ontario. Current Oncology. 31:4656-4674. 2024
- Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy. BMC Cancer. 24:984. 2024
- The Nurse Practitioner Role in Complex Malignant Hematology: A Qualitative Descriptive Study. Seminars in Oncology Nursing. 40:151625-151625. 2024
- A structured oral chemotherapy teaching tool to improve adherence in adults with multiple myeloma: A pilot randomized controlled trial. Journal of Geriatric Oncology. 15:101735-101735. 2024
- Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphomas. Blood. 140:8036-8037. 2022
- Disparities in treatment patterns and outcomes among younger and older adults with newly diagnosed multiple myeloma: A population-based study. Journal of Geriatric Oncology. 12:508-514. 2021
- First-Line Therapy, Autologous Stem-Cell Transplantation, and Post-Transplantation Maintenance in the Management of Newly Diagnosed Mantle Cell Lymphoma. Current Oncology. 27:632-644. 2020
- First-Line Therapy, Autologous Stem-Cell Transplantation, and Post-Transplantation Maintenance in the Management of Newly Diagnosed Mantle Cell Lymphoma.. Current Oncology. 27:632-644. 2020
- Impact of rarity on Canadian oncology health technology assessment and funding. International Journal of Technology Assessment in Health Care. 36:404-409. 2020
- Cost-effectiveness analysis of rituximab with methotrexate, cytarabine and thiotepa for the treatment of patients with primary central nervous system lymphoma. Leukemia and Lymphoma. 61:1097-1107. 2020
- Improved survival in overweight and obese patients with aggressive B-cell lymphoma treated with rituximab-containing chemotherapy for curative intent. Leukemia and Lymphoma. 60:1399-1408. 2019
- Impact of a Novel Prioritization Framework on Clinician-Led Oncology Drug Submissions. Current Oncology. 26:155-161. 2019
- COMPARISON OF FRAILTY SCORES IN NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA: A REVIEW. Journal of Frailty and Aging. 8:1-7. 2019
- The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group. Leukemia and Lymphoma. 58:1358-1365. 2017
- Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12*. Leukemia and Lymphoma. 58:64-69. 2017
- Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline. Clinical Oncology. 29:e13-e28. 2017
- Approach to evaluation of fever in ambulatory cancer patients receiving chemotherapy: A systematic review. Cancer Treatment Reviews. 51:35-45. 2016
- Approach to Fever Assessment in Ambulatory Cancer Patients Receiving Chemotherapy: A Clinical Practice Guideline. Current Oncology. 23:280-285. 2016
- Plerixafor for Autologous Stem-Cell Mobilization and Transplantation for Patients in Ontario. Current Oncology. 23:409-430. 2016
- A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191. Leukemia and Lymphoma. 57:1463-1466. 2016
- Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12. Blood. 126:733-738. 2015
- An Open-Label Expanded-Access Trial of Bendamustine in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia: BEND-ACT. Current Oncology. 22:260-271. 2015
- Gemcitabine/Dexamethasone/Cisplatin vs Cytarabine/Dexamethasone/Cisplatin for Relapsed or Refractory Aggressive-Histology Lymphoma: Cost-Utility Analysis of NCIC CTG LY.12. Journal of the National Cancer Institute. 107:djv106. 2015
-
Thalidomide‐prednisone maintenance following autologous stem cell transplant for
M ultipleM yeloma: effect on thrombin generation and procoagulant markers inNCIC CTG MY .10. British Journal of Haematology. 168:511-517. 2015 - Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12. Journal of Clinical Oncology. 32:3490-3496. 2014
- Bortezomib in Multiple Myeloma: Systematic Review and Clinical Considerations. Current Oncology. 21:573-603. 2014
- Extracorporeal photopheresis in the management of graft-versus-host disease. Current Oncology. 21:310-310. 2014
- Bortezomib in Multiple Myeloma: A Practice Guideline. Clinical Oncology. 26:110-119. 2014
- The Use of Preoperative Erythropoiesis-Stimulating Agents (ESAs) in Patients Who Underwent Knee or Hip Arthroplasty. Journal of Arthroplasty. 28:1463-1472. 2013
- Erythropoiesis-stimulating agents (ESAs): Do they still have a role in chemotherapy-induced anemia (CIA)?. Critical Reviews in Oncology/Hematology. 87:132-139. 2013
- Practical Approaches to the Use of Lenalidomide in Multiple Myeloma: A Canadian Consensus. Advances in Hematology. 2012:1-14. 2012
- Corrigendum. Leukemia and Lymphoma. 52:1160-1160. 2011
- A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). Leukemia and Lymphoma. 52:394-399. 2011
- Bortezomib in Relapsed or Refractory Waldenström's Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia. 9:74-76. 2009
- A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood. 113:1564-1573. 2009
- Canadian Supportive Care Recommendations for the Management of Neutropenia in Patients with Cancer. Current Oncology. 15:9-23. 2008
- Canadian Supportive Care Recommendations for the Management of Anemia in Patients with Cancer. Current Oncology. 14:209-217. 2007
- Bortezomib Is Active in Patients With Untreated or Relapsed Waldenström's Macroglobulinemia: A Phase II Study of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology. 25:1570-1575. 2007
- A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Annals of Oncology. 18:116-121. 2007
- Development of adapted RECIST criteria to assess response in lymphoma and their comparison to the International Workshop Criteria. Leukemia and Lymphoma. 48:513-520. 2007
- Bortezomib is active in Waldenstrom’s Macroglobulinemia (WM)—Results of a National Cancer Institute of Canada (NCIC) phase II study in previously untreated or treated WM. Journal of Clinical Oncology. 24:7543-7543. 2006
- Are Oral Bisphosphonates Effective in Improving Lumbar Bone Mineral Density in Breast Cancer Survivors With Osteopenia or Osteoporosis?. Journal of Obstetrics and Gynaecology Canada. 27:759-764. 2005
- An Evaluation of Age-related Differences in Quality of Life Preferences in Patients with Non-Hodgkin's Lymphoma. Leukemia and Lymphoma. 45:2471-2476. 2004
- Flavopiridol in Untreated or Relapsed Mantle-Cell Lymphoma: Results of a Phase II Study of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology. 21:1740-1745. 2003
- Cost-effectiveness of a Transplantation Strategy Compared to Melphalan and Prednisone in Younger Patients with Multiple Myeloma. Leukemia and Lymphoma. 44:29-37. 2003
- Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy.. Journal of Clinical Oncology. 21:35-40. 2003
- A review of randomized controlled trials using therapeutic apheresis*. Transfusion Medicine Reviews. 16:200-229. 2002
- The Role of High-Dose Chemotherapy and Stem-Cell Transplantation in Patients with Multiple Myeloma: A Practice Guideline of the Cancer Care Ontario Practice Guidelines Initiative. ACP journal club. 136:619-619. 2002
- Chemotherapy for Older Patients with Newly Diagnosed, Advanced-Stage, Aggressive-Histology Non-Hodgkin Lymphoma. ACP journal club. 136:144-144. 2002
- Understanding outcome measures. Growth Hormone and IGF Research. 2:172-176. 2001
- Treatment Strategies in Elderly Patients with Aggressive Histology Lymphoma. Annals of Hematology. 80:B86-B88. 2001
- Assessment of clinical trial inclusion criteria to a cohort of lymphoma patients undergoing autologous transplantation: are trial results generalized to other patient populations?. Blood. 96. 2000
- Seropositive symmetrical inflammatory polyarthritis appearing after treatment with fludarabine in a patient with non-hodgkin's lymphoma. Blood. 96. 2000
- Superior Sagittal Sinus Thrombosis Occurring at High Altitude Associated with Protein C Deficiency. Acta Haematologica. 102:104-106. 1999
- Use of rituximab in the treatment of lymphoma: An evidence summary. Current Oncology. 6:228-235. 1999
- PML/RARα APL with undifferentiated morphology and stem cell immunophenotype. Leukemia. 12:1492-1493. 1998
- Respiratory Failure Following Vinorelbine Tartrate Infusion in a Patient With Non-small Cell Lung Cancer. Chest. 112:846-848. 1997
- Pulmonary Embolism With Duplicated Inferior Vena Cava. Chest. 109:1111-1113. 1996
-
preprints